GlassScriptPhysician profile
John P Hanna
NPI 1699086058
$3,464.43
in general payments reported to CMS, 2019-2025
22 companies · $832 in 2025
The $832 reported for 2025 was more than what 77% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $176 · 2021: $359 · 2022: $708 · 2023: $535 · 2024: $633 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905 · Education: $54.95 · Consulting Fee: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.03 |
| Education | $54.95 |
| Consulting Fee | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $862.74 | 2021-2025 | Nucala |
| Genzyme Corporation | $564.61 | 2019-2025 | |
| Aerin Medical INC. | $539.91 | 2022-2025 | |
| Inspire Medical Systems, INC. | $435.89 | 2023-2025 | Inspire |
| Medtronic USA, INC. | $150.00 | 2020 | |
| Optinose US, INC. | $145.22 | 2022-2023 | |
| Intersect Ent, INC. | $138.07 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $115.16 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $107.06 | 2025 | Fasenra |
| Stryker Corporation | $92.96 | 2019-2024 | Audion Et Dilation System, Scopis Ent |
| Medtronic, INC. | $75.99 | 2021-2023 | Surgipro Ll, Sinuva |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Shire North American Group INC | $43.44 | 2019 | |
| Boston Scientific Corporation | $23.84 | 2023 | Varithena Administration Pack |
| Phadia US INC. | $20.77 | 2023 | Immunocap |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $16.66 | 2023 | Xolair |
| Kaleo, INC. | $15.15 | 2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $14.54 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.48 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.57 | 2019 | |
| Alk-Abello, INC | $11.42 | 2020 | |
| Glenmark Therapeutics INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.